•
Jun 30, 2023

Natera Q2 2023 Earnings Report

Reported strong Q2 2023 results with revenue growth and improved gross margin.

Key Takeaways

Natera reported a strong second quarter with a 31.9% increase in total revenues, driven by a 32.7% increase in product revenues. The company processed approximately 617,200 tests and reported a net loss of $110.8 million, an improvement compared to the previous year. Natera is raising its full year revenue guidance.

Served over 600,000 patients in Q2 2023.

Delivered significant year-over-year growth in volumes and revenues.

Improved gross margin.

Reduced quarterly cash burn.

Total Revenue
$261M
Previous year: $198M
+31.9%
EPS
-$0.97
Previous year: -$1.5
-35.3%
Tests Processed
617.2K
Previous year: 499.9K
+23.5%
Tests Accessioned
599K
Previous year: 484K
+23.8%
Total Tests Reported
594.9K
Previous year: 461.3K
+29.0%
Gross Profit
$118M
Previous year: $89M
+32.9%
Cash and Equivalents
$736M
Previous year: $639M
+15.2%
Free Cash Flow
-$87.4M
Previous year: -$119M
-26.4%
Total Assets
$1.25B
Previous year: $1.07B
+17.0%

Natera

Natera

Forward Guidance

Natera is raising its expectations for 2023 total revenue from $995 million to $1.015 billion to a new range of $1.015 billion to $1.035 billion. The Company expects 2023 gross margin to be approximately 41% to 44% of revenues; selling, general and administrative costs to be approximately $540 million to $580 million; research and development costs to be approximately $325 million to $345 million; and net cash consumption to be approximately $300 million to $325 million.